BRIEF published on 09/02/2026 at 07:05, 2 hours 6 minutes ago La FDA américaine accorde la désignation de procédure accélérée à BioVersys pour le BV100 FDA BV100 BioVersys CRABC Voie Rapide
BRIEF published on 09/02/2026 at 07:05, 2 hours 6 minutes ago US FDA Grants Fast-Track Designation to BioVersys for BV100 FDA Fast Track BV100 BioVersys CRABC
PRESS RELEASE published on 09/02/2026 at 07:00, 2 hours 11 minutes ago BioVersys granted Fast-Track Designation from US FDA for BV100 BioVersys AG receives Fast-Track Designation from US FDA for BV100, a potential anti-infective agent targeting carbapenem-resistant Acinetobacter baumannii infections BioVersys AG BV100 Antibacterial Products US FDA Fast-Track Designation
BRIEF published on 08/26/2026 at 07:05, 7 days 2 hours ago BioVersys annoncera ses résultats financiers et son point d'activité pour le premier semestre 2026. Résultats Financiers Conférence Téléphonique BioVersys Nouveaux Antibactériens Résistance Aux Médicaments Multiples
BRIEF published on 08/26/2026 at 07:05, 7 days 2 hours ago BioVersys to Announce Half-Year 2026 Financial Results and Business Update Financial Results Conference Call BioVersys Novel Antibacterials Multi-drug Resistant
PRESS RELEASE published on 08/26/2026 at 07:00, 7 days 2 hours ago BioVersys to report its half-year 2026 financial results, provide a business update and host a conference call BioVersys AG to report half-year 2026 financial results, provide business update, and host conference call. Focus on novel antibacterial products for MDR bacteria infections Financial Results Conference Call BioVersys AG Antibacterial Products MDR Bacteria
BRIEF published on 08/25/2026 at 07:05, 8 days 2 hours ago BioVersys Announces Financial Results and Business Update Financial Results Conference Call Biopharmaceuticals Antibacterial Products BioVersys
BRIEF published on 08/25/2026 at 07:05, 8 days 2 hours ago BioVersys annonce ses résultats financiers et une mise à jour de ses activités Résultats Financiers Conférence Téléphonique Produits Biopharmaceutiques Produits Antibactériens BioVersys
PRESS RELEASE published on 08/25/2026 at 07:00, 8 days 2 hours ago BioVersys to report its half-year 2026 financial results, provide a business update and host a conference call BioVersys AG to report its half-year 2026 financial results, provide a business update, and host a conference call. Details of the call and webcast included Conference Call Half-year Results BioVersys AG Antibacterial Products Multi-drug Resistant Bacteria
BRIEF published on 04/30/2026 at 19:05, 4 months 1 day ago BioVersys Announces Successful AGM Approvals Leadership Changes Shareholders' Support BioVersys AGM Antibacterial Development Board Approvals
Published on 09/01/2026 at 23:05, 10 hours 6 minutes ago Aton Announces US$30M Credit Facility with OU Moonrider
Published on 09/01/2026 at 22:30, 10 hours 41 minutes ago Algo Grande Copper Closes Oversubscribed Private Placement for $4.786 Million
Published on 09/01/2026 at 22:15, 10 hours 56 minutes ago NuRAN Wireless Announces Plans to Voluntarily Delist from the Canadian Securities Exchange
Published on 09/01/2026 at 16:10, 17 hours 1 minute ago Sparton Signs Definitive Morrison Silver Mine Option and Joint Venture Agreement with Glen Eagle; Appoints Vice President, Corporate Development
Published on 09/02/2026 at 09:00, 11 minutes ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): HOLD
Published on 09/02/2026 at 08:59, 12 minutes ago Advanced Blockchain AG: Mathias Roch elected new Chairman of the Supervisory Board
Published on 09/02/2026 at 08:05, 1 hour 6 minutes ago World's First Tri-Fold Full HD Pocket Projector: Aurzen ZIP Pro Takes Over Times Square
Published on 09/02/2026 at 07:43, 1 hour 27 minutes ago Accor launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2032 for a nominal amount of €380 million and a concurrent partial repurchase offer with respect to its outstanding OCEANEs due 2027 by
Published on 09/02/2026 at 07:43, 1 hour 27 minutes ago Accor lance une émission d’obligations à option de conversion en actions nouvelles et/ou d’échange en actions existantes (OCEANEs) à échéance 2032 pour un montant nominal de 380 millions d’euros et une offre concomitante de rachat partiel de s
Published on 09/01/2026 at 19:00, 14 hours 11 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 09/01/2026 at 19:00, 14 hours 11 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 09/01/2026 at 18:18, 14 hours 53 minutes ago TF1 - Déclaration mensuelle des actions et droits de vote - Août 2026
